Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
作者信息
Hälbig Thomas D, Tse Winona, Olanow C Warren
机构信息
Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
出版信息
Neurol Clin. 2004 Oct;22(3 Suppl):S1-S17. doi: 10.1016/j.ncl.2004.07.002.
PMID:15501359
Abstract
摘要
相似文献
1
Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
Neurol Clin. 2004 Oct;22(3 Suppl):S1-S17. doi: 10.1016/j.ncl.2004.07.002.
2
Future therapies for Parkinson's disease.
Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. doi: 10.1016/j.ncl.2004.05.005.
3
Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Mov Disord. 1998;13 Suppl 1:55-8.
4
Clinical aspects of neuroprotection in Parkinson's disease.
J Neural Transm Suppl. 1994;43:163-9.
5
Treatment challenges in early stage Parkinson's disease.
Neurol Clin. 2004 Oct;22(3 Suppl):S19-33. doi: 10.1016/j.ncl.2004.05.002.
6
Dihydroergocryptine in the treatment of Parkinson's disease.
J Neural Transm Suppl. 1995;45:239-45.
7
New small molecules for the treatment of Parkinson's disease.
Expert Opin Investig Drugs. 2010 Sep;19(9):1077-86. doi: 10.1517/13543784.2010.504711.
8
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021.
9
[Drug therapy of Parkinson's disease].
Duodecim. 1997;113(18):1827-34.
10
Levodopa--toxic or neuroprotective?
Nat Clin Pract Neurol. 2006 Oct;2(10):518-9. doi: 10.1038/ncpneuro0293.
引用本文的文献
1
Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.
J Clin Neurol. 2005 Oct;1(2):107-20. doi: 10.3988/jcn.2005.1.2.107. Epub 2005 Oct 20.
2
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
Genes Brain Behav. 2008 Mar;7(2):129-51. doi: 10.1111/j.1601-183X.2007.00342.x. Epub 2007 Aug 3.
Zotero 插件